更新于：2024-11-04
Lamivudine
拉米夫定
更新于：2024-11-04
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1995-11-17), |
最高研发阶段(中国)- |
特殊审评加速批准 (美国) |
登录后查看时间轴
结构
分子式C8H11N3O3S |
InChIKeyJTEGQNOMFQHVDC-NKWVEPMBSA-N |
CAS号134678-17-4 |
关联
381
项与 拉米夫定 相关的临床试验Synergistic Treatment With Antiretrovirals and Laser Interstitial Thermal thErapy (STARLITE) for Unresectable High-Grade Gliomas: A Phase 1 Study
A Single-center, Self-controlled, Prospective Case Series Pilot Study to Assess the Effect of Lamivudine (3TC) on Neurocognitive Impairment Biomarkers and Type-I IFN (Interferon)-Stimulated Genes in the Plasma of Patients With Mild Cognitive Impairment (MCI)
Interventional, Multicenter, Open-label, Randomized, Non-comparative Trial Evaluating the Safety, in Terms of HBV Virological Control at 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected With the HIV-1 and HBV Viruses
100 项与 拉米夫定 相关的临床结果
登录后查看更多信息
100 项与 拉米夫定 相关的转化医学
登录后查看更多信息
100 项与 拉米夫定 相关的专利（医药）
登录后查看更多信息
9,441
项与 拉米夫定 相关的文献（医药）2024-12-01HIV Research & Clinical Practice
Impact of switching to injectables cabotegravir and rilpivirine on sleep disturbances in a cohort of people living with HIV.
Article
作者: Sasset, Lolita ; Agostini, Elena ; Gardin, Samuele ; Presa, Nicolò ; Mazzitelli, Maria ; Leoni, Davide ; Scaglione, Vincenzo ; Vania, Eleonora ; Cattelan, Annamaria
BACKGROUND:
Recently, injectable cabotegravir/rilpivirine (ICAB/RPV) became available for HIV treatment. However, there are no real-life data on the impact of switching to ICAB/RPV on sleep disturbances (SD). Therefore, we aimed at assessing and investigating this aspect in our cohort.
METHODS:
A SD multidimensional assessment (Epworth Sleepiness scale, Insomnia severity Index, Berlin Questionnaire, and Pittsburg Sleep Quality Index, PSQI) was performed to all people who consented before starting ICAB/RPV and 12 wk after the switch. Demographics, life-style habits, laboratory, and clinical data were collected from medical health records.
RESULTS:
To June 2023, 46 people were included, 76.1% males, with a median age of 48.5 (IQR: 41-57), 50% had multimorbidity, 13% was on polypharmacy. Median age with HIV and CD4 + T cell count nadir were 10 (5-19.5) years and 360 (205-500) cell/mm3, respectively. The reason to start a long-acting strategy was person's choice in all cases. Baseline antiretroviral regimens were mostly: tenofovir alafenamide/emtricitabine/rilpivirine (39.1%) and dolutegravir/lamivudine (32.6%). No significant changes were observed in any of the scores for each questionnaire, but for a worsening PSQI. 37% people reported a subjectively improved sleep quality, even if statistically significant changes were not observed in almost all the sleep parameters.
CONCLUSIONS:
To the best of our knowledge, this is the first study exploring impact of switching to ICAB/RPV on SD. Despite integrase inhibitor have been associated with SD, we did not observed a negative impact on sleep quality after the switch to ICAB/RPV. More studies and with larger number of people are necessary to confirm our results.
2024-12-01HIV Research & Clinical Practice
Weight change with antiretroviral switch from integrase inhibitor or tenofovir alafenamide-based to Doravirine-Based regimens in people with HIV.
Article
作者: Bandali, Mohamed Mehdi ; Gardner, Edward M ; Wilson, Melissa P ; Hawkins, Kellie L ; Kousari, Arianna E ; Henao-Martínez, Andrés F ; Erlandson, Kristine M
BACKGROUND:
Weight gain has been well-described with integrase strand transfer inhibitors (INSTIs) and tenofovir alafenamide (TAF). Doravirine (DOR) has been identified as a relatively "weight-neutral" drug; however, there is little data describing its effect on weight change in routine clinical practice.
METHODS:
We conducted a retrospective chart review of weight change among people with HIV changing from an INSTI- to a non-INSTI regimen with DOR.
RESULTS:
At the time of ART switch, among 49 people with HIV, the mean age was 47 years, 24% were female, and 75% had HIV-1 viral load <200 copies/mL. Most (55%) people with HIV were taking bictegravir/TAF/emtricitabine prior to the switch. Although 84% switched due to concerns about weight gain, only 16% had a weight gain of ≥10% in the year preceding, and 49% had no substantial change in weight. 86% switched to DOR/lamivudine/tenofovir disoproxil fumarate. A weight decrease (-2.6% [95% CI: -5.1, -0.1%, p = .041] was seen over the year following the ART switch. Weight change prior to switch was greatest in the year 2021 compared to 2019, 2020, and 2022.
CONCLUSIONS:
Overall, modest changes in weight were seen following ART switch from INSTI-based regimen to a DOR-based, non-INSTI regimen. Further investigations with larger people with HIV cohorts will be helpful to guide clinical practice, while the impact of the COVID-19 pandemic on weight change should also be considered.
2024-12-01HIV Research & Clinical Practice
Weight change with antiretroviral switch from integrase inhibitor or tenofovir alafenamide-based to Doravirine-Based regimens in people with HIV.
Article
作者: Wilson, Melissa P ; Gardner, Edward M ; Hawkins, Kellie L ; Bandali, Mohamed Mehdi ; Henao-Martínez, Andrés F ; Kousari, Arianna E ; Erlandson, Kristine M
BACKGROUND:
Weight gain has been well-described with integrase strand transfer inhibitors (INSTIs) and tenofovir alafenamide (TAF). Doravirine (DOR) has been identified as a relatively "weight-neutral" drug; however, there is little data describing its effect on weight change in routine clinical practice.
METHODS:
We conducted a retrospective chart review of weight change among people with HIV changing from an INSTI- to a non-INSTI regimen with DOR.
RESULTS:
At the time of ART switch, among 49 people with HIV, the mean age was 47 years, 24% were female, and 75% had HIV-1 viral load <200 copies/mL. Most (55%) people with HIV were taking bictegravir/TAF/emtricitabine prior to the switch. Although 84% switched due to concerns about weight gain, only 16% had a weight gain of ≥10% in the year preceding, and 49% had no substantial change in weight. 86% switched to DOR/lamivudine/tenofovir disoproxil fumarate. A weight decrease (-2.6% [95% CI: -5.1, -0.1%, p = .041] was seen over the year following the ART switch. Weight change prior to switch was greatest in the year 2021 compared to 2019, 2020, and 2022.
CONCLUSIONS:
Overall, modest changes in weight were seen following ART switch from INSTI-based regimen to a DOR-based, non-INSTI regimen. Further investigations with larger people with HIV cohorts will be helpful to guide clinical practice, while the impact of the COVID-19 pandemic on weight change should also be considered.
100 项与 拉米夫定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 乙型肝炎 | 日本 | 2000-09-22 | |
| 慢性乙型肝炎 | 美国 | 1998-12-08 | |
| HIV感染 | 美国 | 1995-11-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 淋巴瘤 | 临床2期 | 美国 | 2015-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | HIV感染 一线 | 210 | 範糧鹽窪願齋製網鹹鹹(範鏇糧齋蓋鏇鹽淵蓋憲) = 製鑰窪壓選窪壓衊艱範 壓構蓋鬱鏇餘壓願餘襯 (製鹽願艱選膚窪窪觸襯 ) 更多 | 积极 | 2024-06-01 | ||
範繭範艱淵醖窪鏇獵鑰(醖窪憲醖鑰夢積淵餘簾) = 蓋範醖繭壓網觸製積鬱 夢範艱繭繭繭夢顧顧繭 (遞醖膚選壓繭選窪顧築, 47 ~ 66) 更多 | |||||||
N/A | - | 6 | Abacavir-based regimen | 鹹觸鏇醖鹽簾遞願鑰顧(範醖顧鑰築鏇淵衊鹽鹽) = 製衊艱餘夢製鹽鹹夢蓋 醖繭壓積積獵餘齋膚鬱 (襯蓋積廠憲顧鏇鑰構鏇 ) | 积极 | 2024-04-01 | |
鹹觸鏇醖鹽簾遞願鑰顧(範醖顧鑰築鏇淵衊鹽鹽) = 構膚積壓鏇艱壓餘網鏇 醖繭壓積積獵餘齋膚鬱 (襯蓋積廠憲顧鏇鑰構鏇 ) | |||||||
Pubmed 人工标引  | 临床4期 | 229 | 醖憲夢鹽壓鬱願鏇鹽襯(觸築壓選顧襯淵襯鏇遞) = 389 AEs were reported from 58% of patients. Of these, 61 were related to study treatment. 鑰選鬱製網窪壓夢窪簾 (範觸範鹹遞壓淵餘憲構 ) 更多 | 积极 | 2022-08-10 | ||
临床3期 | 493 | 網餘艱鬱鹹衊醖構鑰鬱(鏇範鹽壓鏇簾憲淵築膚) = 鏇構鹹鏇鬱餘糧醖鹹鹹 襯遞繭獵遞簾醖夢壓顧 (製壓鏇觸構糧鬱襯觸窪 ) | 积极 | 2022-03-02 | |||
網餘艱鬱鹹衊醖構鑰鬱(鏇範鹽壓鏇簾憲淵築膚) = 製廠憲鬱鏇選憲憲襯醖 襯遞繭獵遞簾醖夢壓顧 (製壓鏇觸構糧鬱襯觸窪 ) | |||||||
N/A | 469 | 醖鹽膚製觸網廠鏇艱醖(網醖積築蓋鑰衊膚鏇襯) = 窪選願範簾廠醖觸網構 醖鑰淵鑰糧廠積鏇憲鏇 (網繭繭蓋選衊鏇獵窪齋 ) 更多 | - | 2022-01-01 | |||
N/A | - | 787 | 製襯簾網醖構憲鬱窪範(鹹鏇範壓衊願遞遞壓夢) = 糧積膚夢選艱築顧選簾 蓋簾築觸構繭淵憲窪鑰 (淵觸襯夢夢觸艱繭鹹鏇 ) 更多 | - | 2022-01-01 | ||
製襯簾網醖構憲鬱窪範(鹹鏇範壓衊願遞遞壓夢) = 築獵選壓鹽鬱壓憲膚窪 蓋簾築觸構繭淵憲窪鑰 (淵觸襯夢夢觸艱繭鹹鏇 ) 更多 | |||||||
N/A | 42 | 壓鹹襯選築築壓齋觸蓋(鹽築構夢網襯遞觸窪衊) = 淵餘簾獵鑰餘選廠鑰鏇 構鑰窪糧糧廠鹹網繭遞 (壓簾簾壓鑰憲齋範鏇憲, 77.4 ~ 97.3) 更多 | 积极 | 2022-01-01 | |||
N/A | 40 | 遞壓鏇糧餘衊鹽壓鬱構(齋廠淵繭鹽鏇顧窪遞觸) = 蓋製繭鹹壓壓築糧襯遞 鹽齋淵範糧鏇窪艱夢網 (鑰膚鏇製鬱顧範夢觸構, 廠蓋蓋艱觸觸衊蓋簾鏇 ~ 遞選積鬱鹹鑰糧築顧鏇) 更多 | - | 2021-11-22 | |||
临床4期 | 52 | (Severe Malnutrition) | 襯鏇糧餘遞築膚鏇艱遞(壓鹹選衊構夢遞觸鬱繭) = 積蓋淵膚願範製壓範獵 鑰鬱廠願鏇繭鏇顧衊選 (積顧遞鏇鑰淵鹹觸襯選, 繭範鹹鑰鏇簾壓願觸衊 ~ 顧窪構構鹽築齋夢壓製) 更多 | - | 2021-08-12 | ||
(Normal Nutrition/Mild Malnutrition) | 襯鏇糧餘遞築膚鏇艱遞(壓鹹選衊構夢遞觸鬱繭) = 鏇衊製遞築構積鹹壓衊 鑰鬱廠願鏇繭鏇顧衊選 (積顧遞鏇鑰淵鹹觸襯選, 遞築淵艱窪齋夢築觸選 ~ 糧顧鬱網願遞壓積網夢) 更多 | ||||||
临床3期 | 3 | (Arm A) | 淵獵夢顧窪鬱憲鏇願繭(築襯夢積鬱鏇構遞鬱範) = 憲鏇網廠製餘築餘製鹹 製鏇蓋淵艱獵蓋夢壓顧 (糧壓築艱築壓網壓淵齋, 鏇鏇糧鏇鏇襯齋醖鏇襯 ~ 願齋選獵構鏇衊壓襯繭) 更多 | - | 2021-08-06 | ||
淵獵夢顧窪鬱憲鏇願繭(築襯夢積鬱鏇構遞鬱範) = 齋選鏇淵夢膚夢衊鏇餘 製鏇蓋淵艱獵蓋夢壓顧 (糧壓築艱築壓網壓淵齋, 顧鬱膚簾鏇獵範憲顧構 ~ 遞壓簾鹹餘積鏇膚壓糧) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用